

Synthesis of Water-Soluble Chiral DOTA Lanthanide Complexes with Predominantly Twisted Square Antiprism Isomers and Circularly Polarized Luminescence

Lixiong Dai,^{†,‡} Junhui Zhang,^{†,‡} Yuqing Chen,[‡] Lewis E. Mackenzie,[§] Robert Pal,[§] and Ga-Lai Law^{*,†,‡,§}[†]The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518000, People's Republic of China[‡]State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China[§]Department of Chemistry, Durham University, South Road, Durham DH1 3LE, United Kingdom

Supporting Information

ABSTRACT: One-step cyclization of a tetraazamacrocycle **5** with 70% yield in a 25-g scale was performed. Its chiral DOTA derivatives, **L4**, has ~93% of TSAP coordination isomer in its Eu(III) and Yb(III) complexes in aqueous solution. $[\text{GdL4}]^{5-}$ exhibits a high relaxivity, making it a promising and efficient MRI contrast agent. High luminescence dissymmetry factor (g_{lum}) values of 0.285 ($\Delta J = 1$) for $[\text{TbL3}]^{-}$ and 0.241 ($\Delta J = 1$) for $[\text{TbL4}]^{5-}$ in buffer solutions were recorded.

The scaffold of 1,4,7,10-tetraazacyclododecane-*N,N,N,N*-tetraacetic acid (DOTA) is one of the most vastly studied macrocyclic ligands in coordination chemistry, because of its favorable chelating effect. Hence, numerous types of metal-DOTA complexes are known to exhibit excellent stability under physiological conditions, hence dominating the field of study for biomedical applications.¹ A notable example is the use of $[\text{GdDOTA}]^{-}$ as a clinical contrast agent in magnetic resonance imaging (MRI).² DOTA derivatives are also used as chelators of radiometals and trivalent lanthanide ions (Ln) for diagnosis and therapy applications, such as the theranostic pair $^{68}\text{Ga}/^{177}\text{Lu}$ -labeled DOTA-TATE, which were approved by U.S. Food and Drug Administration (FDA).³ Recently, in one of our studies, we showed that, by introducing chiral groups into DOTA, the stability of the complexes was tremendously enhanced.⁴ This has drawn increasing attention to the properties of chiral groups that can be engineered on the carbons of the macrocyclic ring or on the pendant side arms.⁵ Interestingly, our chiral DOTAs also could control the coordination geometry such that only two noninterconvertible isomers can be formed. This is important since obtaining pure stereoisomers of chiral luminescent complexes is crucial for circularly polarized luminescence (CPL) applications and ideal for use as protein tags for nuclear magnetic resonance (NMR) studies.^{6–8} Regarding T_1 -shortening contrast agents for MRI, the conformation of the lanthanide complexes also plays a significant role in the water exchange rate k_{ex} ($k_{\text{ex}} = 1/\tau_M$).⁹ It has been shown that the k_{ex} value in the twisted square antiprismatic (TSAP) configuration is 10–100 times faster than the square antiprism (SAP), which is useful as T_1 -shortening contrast agents.¹⁰ However, the synthetic efficiency

of these chiral DOTAs is still very low, and the chiral DOTA complexes with four benzyl groups, with predominantly TSAP isomers, are not water-soluble, this limits the scope of their bioapplications. Herein, we present a new generation of chiral DOTA complexes (Figure 1) with phenyl substituents with the





Figure 1. Structures of synthesized lanthanide chiral DOTA complexes ($[\text{LnL1}]^{-}$ – $[\text{LnL4}]^{5-}$). [Ln = Eu(III), Tb(III), Yb(III), and Gd(III)]. Note that, for the sake of clarity, the counterions are not depicted.]

objective of improving their water solubility; their coordination geometry and relaxation behavior, as well as the CPL properties, were also studied.

The ligand **L1** and its complexes were synthesized according to our previous report.⁴ Based on **L1**, we introduced a hydrophilic amino group on each of the phenyl rings to get **L2**. As shown in Scheme 1, the 12-membered **2** was synthesized

Received: June 20, 2019


Scheme 1. Synthesis of $[\text{LnL2}]^-$ [$\text{Ln} = \text{Eu(III)}$, Yb(III) , and Gd(III)]

from the aziridine compound **1** through a cyclization reaction (see Scheme S1 in the Supporting Information). We have two methods that were optimized in our previous study:⁴ Method A, which uses benzene as a solvent and boron trifluoride diethyl etherate as a catalyst where the reaction is performed at $80\text{ }^\circ\text{C}$ for 16 h; and method B, which uses acetonitrile as a solvent and *p*-toluenesulfonic acid monohydrate as a catalyst where the reaction is performed at ambient temperature for 6 days. Although both conditions could get reasonable yields, the workup for the first method is more complicated and benzene, which is a highly toxic solvent, is needed, so we chose the second method in scaling-up our reactions. The four nitro groups were then reduced to amino groups by zinc powder in acetic acid and subsequently protected by acetic anhydride. The four benzyl protecting groups were then deprotected by palladium hydroxide on carbon, and ammonium formate with trifluoroethanol was used as a solvent, since we determined that this solvent is more efficient than the other alcohol solvents (such as methanol and ethanol), and the compound has better solubility.

This resulted in the chiral cyclen (1,4,7,10-tetraazacyclodecane) compound **3**. **3** was reacted with *tert*-butyl 2-


bromoacetate in the presence of potassium carbonate to get the fully protected DOTA compound, and acetate groups were then deprotected under anhydrous conditions,¹¹ which gave **L2** after deprotection by TFA. Complexations were performed under neutral conditions. Despite having a better solubility than $[\text{GdL1}]^-$, $[\text{GdL2}]^-$ is not completely water-soluble ($<0.1\text{ mM}$).

Although the four amino groups could be used to conjugate with even higher hydrophilic compounds to improve the water solubility, the ratio of TSAP/SAP in the complexes of $[\text{EuL2}]^-$ and $[\text{YbL2}]^-$ decreased drastically, compared to the complexes of **L1** (vide infra); this phenomenon was also observed in similar systems with amino groups,⁴ so we changed our design to methoxyl groups on the *para*-position of the phenyl rings. These electron-donating groups make it possible to perform sulfonylation reactions at their nearby positions, because sulfonylation is one of the best ways to improve the water solubility of a compound.¹² After sulfonylation, the complexes exhibit the following solubility in ascending order: $[\text{GdL1}]^- \approx [\text{GdL3}]^- < [\text{GdL2}]^- < [\text{GdL4}]^{5-}$ (see the Supporting Information). To test the effect of methoxy groups on the *para*-position of the phenyl groups on the TSAP/SAP ratio, **L3** and its complexes were synthesized, as shown in Scheme S3 in the Supporting Information. Note that the chiral cyclen compound **5** was published as a total synthesis.¹³ Similar to **L1** and its complexes, the single crystal structure of compound **5** showed that the four methoxybenzyl groups on the macrocyclic ring were located on one side of the ring, and the other four benzyl groups on the nitrogen positions are located on the other side of the ring.¹³ To our interest, the cyclization reaction of this compound gave almost quantitative conversion (Scheme 2) and, as monitored by TLC, the reaction was

Scheme 2. Synthesis of Compound 5

almost finished after stirring at ambient temperature for 2 days with no obvious byproduct observed. The workup was also very simple: 2% NaHCO_3 was poured into the reaction mixture to quench the reaction, and, after stirring for 20 min, a simple filtration was performed and the resulting white solid was dried to give the product with 70% yield (filtrate unrecycled). The high yield was maintained after scaling up to four batches of 12.5 g and one batch of 25 g of **4**. This demonstrated the feasibility of large-scale production of this compound, and this is the first time a chiral cyclen compound is obtained in such a high yield and with a simple synthesis.

The sulfonylation reaction was also unexpectedly smooth (as shown in Scheme 3). **5** was dissolved in dry dichloromethane, and chlorosulfonic acid was added dropwise into the reaction mixture at $0\text{--}10\text{ }^\circ\text{C}$. After stirring for 12 h at ambient temperature, the reaction was monitored by mass spectrometry; only the signal of the product and its hydrolyzed products were detected. After successful reactions of the first two steps,

Scheme 3. Synthesis of [LnL4]^{5−} [Ln = Eu(III), Tb(III), Yb(III), and Gd(III)]


the latter steps were performed similarly to the synthesis of **L1** and its complexes.⁴

The TSAP/SAP isomer ratios of the synthesized Eu(III) and Yb(III) complexes were determined by ¹H NMR as the two sets of protons of two geometric isomers could be easily identified on the ¹H NMR spectra.¹⁰ As shown in Figure 2, the TSAP/SAP isomer ratio in [EuL1][−] is 15.1. This ratio decreased to 4.3 in [EuL2][−], because there are four amino groups on the *para*-position of the phenyl groups. We have found that the hydrogen bonds on the amino groups could affect the coordination geometry of the lanthanide complexes.⁴




Figure 2. ¹H NMR spectra (25 °C, 400 MHz, pD 7.0) of (a) [EuL1][−]–[EuL4]^{5−} and (b) [YbL1][−]–[YbL4]^{5−}, showing the variation in the TSAP/SAP isomer ratios. ([LnL4]^{5−} in D₂O; the others are in a mixture of *d*⁶-DMSO–D₂O (~1:1), because of solubility issues.)

While the ratio increased to 7.6 for [EuL3][−], to our expectation, the ratio went back to 14.9 for [EuL4]^{5−}. The TSAP/SAP ratios range from 38.1–0.8–6.3–18.7 in Yb(III) complexes, the trend is very similar to the Eu(III) complexes. Since the ionic radius of Gd(III) is between that of Eu(III) and Yb(III), we could expect the abundance of TSAP isomer in [GdL4]^{5−} would be ~93%. Such a high abundance of TSAP geometry in Gd(III) complex is ideal for use as magnetic resonance imaging (MRI) contrast agents.

Gd(III) complexes are mostly used as *T*₁-shortening MRI contrast agents, and their efficiencies are commonly evaluated in terms of longitudinal relaxivity (*r*₁), which is the enhancement of the water proton relaxation rate (*T*₁^{−1}) in solutions containing 1 mM of the paramagnetic solute.¹⁴ The relaxivity of [GdL4]^{5−} was compared against the commercial available [GdDOTA][−] (Dotarem) (Figure S1 in the Supporting Information). The relaxivity of [GdL4]^{5−} is 6.8 mM^{−1} s^{−1}, which is twice than that of [GdDOTA][−] (3.2 mM^{−1} s^{−1}) under the same conditions (1.5 T, 37 °C). This means [GdL4]^{5−} is more efficient than [GdDOTA][−] as an MRI contrast agent.

Luminescent chiral lanthanide complexes are capable of emitting circularly polarized luminescence (CPL), especially from the magnetic-dipole allowed *f*–*f* transitions, which give higher intensity.⁶ Spherical lanthanide cations can avoid the problem of anisotropy, and, if judiciously designed, can afford high luminescence dissymmetry factor (*g*_{lum}), which is defined as *g*_{lum} = 2(*I*_L – *I*_R)/(*I*_L + *I*_R) (*I*_L and *I*_R are the emission intensity of left- and right-handed circularly polarized light, respectively). Typical *g*_{lum} values of organic compounds are in the range of 10^{−4} – 10^{−3}, while those of chiral lanthanide complexes can reach values of >10^{−1}.¹⁵ As mentioned above, the [LnL3][−] and [LnL4]^{5−} complexes exist as predominantly TSAP isomers, making them promising for use in CPL studies. Pure TSAP isomers of [EuL3][−] and [TbL3][−] were obtained by reversed-phase semipreparative high-performance liquid chromatography (HPLC). Samples for photophysical measurements were prepared in 0.1 M HEPES with 5% DMSO, because of solubility issues. CPL signals from [EuL3][−] could not be detected, because of its very weak emission (Figure S13 in the Supporting Information), which is a result of poor energy transfer due to the large energy gap between the chromophore's triplet state and Eu(III) excited states, the multiple excited states also leads to energy lost from non radiative processes. Alternatively, the emitting state of Tb(III) matches well with the chromophore's triplet state, since, for efficient energy transfer, the ideal energy gap is ~4000 ± 500 cm^{−1}. (See Figure S16 in the Supporting Information.) Figure 3 shows the total emission and CPL spectra of the TSAP isomer of [TbL3][−]. The *g*_{lum} values of the magnetic-dipole-allowed transitions of [TbL3][−] (⁵D₄ → ⁷F₅, Δ*J* = 1) were 0.285 (542.5 nm) and 0.173 (551 nm). [TbL4]^{5−}, with ~93% TSAP isomer, has *g*_{lum} values of 0.241 (542.5 nm) and 0.151 (551 nm). Nevertheless, the spectral characteristics of the emission and CPL spectra of [TbL3][−] and [TbL4]^{5−} are almost identical (see Figure 4). To the best of our knowledge, the *g*_{lum} values, 0.285 and 0.241, are among the highest for Tb(III) complexes.¹⁶ Conversely, although higher *g*_{lum} values were reported for chiral Eu(III) complexes,^{15,17,18} most of them are formed from multicomponent ligands and their solubility and stability in aqueous solution are very poor; moreover, the pure magnetic-dipole nature of the ⁵D₀ → ⁷F₁ transition of Eu(III) renders much weaker emission intensity.




Figure 3. Total emission (lower) and CPL (upper) spectra of TSAP isomer of $[\text{TbL3}]^-$ in 0.1 M of HEPES buffer (with ~5% of DMSO), pH 7.4, $\text{abs} = 0.3$, $\lambda_{\text{ex}} = 280$ nm.




Figure 4. Total emission (down) and CPL (upper) spectra of $[\text{TbL4}]^{5-}$ in 0.1 M of HEPES buffer, pH 7.4, $\text{abs} = 0.3$, $\lambda_{\text{ex}} = 280$ nm.

As a result, our Tb(III) complexes are impressively balanced for practical CPL applications.

In conclusion, we have described an efficient strategy for the synthesis of water-soluble lanthanide chiral DOTA complexes with very high ratio of TSAP coordination geometry. The key intermediate of chiral cyclen **5** with four 4-methoxybenzyl groups was synthesized with high yields in the scale of dozens of grams, and this compound could be easily functionalized to create variations of DOTA chelates. Complexes $[\text{LnL4}]^{5-}$ have very good water solubility and exist as up to 93% of the TSAP isomer. $[\text{GdL4}]^{5-}$ shows very high relaxivity at 1.5 T, 37 °C, while g_{lum} values of $[\text{TbL3}]^-$ and $[\text{TbL4}]^{5-}$ are among the highest for chiral Tb(III) complexes, making them promising for a diverse range of applications, such as MRI, sensing, or CPL applications. Further biological studies and applications of these compounds are currently in progress in our laboratory.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.inorgchem.9b01799.

Experimental procedures, full characterization of products, and NMR spectra (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: ga-lai.law@polyu.edu.hk.

ORCID

Ga-Lai Law: 0000-0002-2192-6887

Author Contributions

G.-L.L. conceived and supervised the project and contributed to the writing of the manuscript. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

G.-L.L. gratefully acknowledge the State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University ((a) University Research Facility in Chemical and Environmental Analysis (UCEA); (b) University Research Facility in Life Sciences (ULS)) and the Natural Science Foundation of China (NSFC, No. 21875201) R.P. would like to acknowledge the Royal Society University Research Fellowships. G.-L. L acknowledges support by a Durham Senior Research Fellowship COFUNDED between Durham University and the European Union, under Grant Agreement No. 609412.

REFERENCES

- (1) (a) Alexander, V. Design and synthesis of macrocyclic ligands and their complexes of lanthanides and actinides. *Chem. Rev.* **1995**, 95, 273–342. (b) Stasiuk, G. J.; Long, N. J. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. *Chem. Commun.* **2013**, 49, 2732–2746.
- (2) (a) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. *Chem. Rev.* **1999**, 99, 2293–2352. (b) Wahsner, J.; Gale, E. M.; Rodriguez-Rodriguez, A.; Caravan, P. Chemistry of MRI contrast agents: Current challenges and new frontiers. *Chem. Rev.* **2019**, 119, 957–1057.
- (3) (a) FDA approves ^{18}F -fluciclovine and ^{68}Ga -DOTATATE products. *J. Nucl. Med.* **2016**, 57 (8), 9N (URL: <http://jnm.snmjournals.org/content/57/8/9N.citation>). (b) FDA approves Lutathera for GEP NET therapy. *J. Nucl. Med.* **2018**, 59 (4), 9N (URL: <http://jnm.snmjournals.org/content/59/4/9N.citation>).
- (4) Dai, L.; Jones, C. M.; Chan, W. T. K.; Pham, T. A.; Ling, X.; Gale, E. M.; Rotile, N. J.; Tai, W. C.-S.; Anderson, C. J.; Caravan, P.; Law, G.-L. Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications. *Nat. Commun.* **2018**, 9, 857.
- (5) (a) Woods, M.; Kovacs, Z.; Zhang, S.; Sherry, A. D. Towards the rational design of magnetic resonance imaging contrast agents: isolation of the two coordination isomers of lanthanide DOTA-type complexes. *Angew. Chem., Int. Ed.* **2003**, 42, 5889–5892. (b) Häussinger, D.; Huang, J.-r.; Grzesiek, S. DOTA-M8: an extremely rigid, high-affinity lanthanide chelating tag for PCS NMR spectroscopy. *J. Am. Chem. Soc.* **2009**, 131, 14761–14767. (c) Göbl, C.; Resch, M.; Strickland, M.; Hartmüller, C.; Viertler, M.; Tjandra, N.; Madl, T.

Increasing the Chemical-Shift Dispersion of Unstructured Proteins with a Covalent Lanthanide Shift Reagent. *Angew. Chem., Int. Ed.* **2016**, *55*, 14847–14851. (d) Opina, A. C. L.; Strickland, M.; Lee, Y.-S.; Tjandra, N.; Byrd, R. A.; Swenson, R. E.; Vasalatiy, O. Analysis of the isomer ratios of polymethylated-DOTA complexes and the implications on protein structural studies. *Dalton Trans* **2016**, *45*, 4673–4687. (e) Müntener, T.; Thommen, F.; Joss, D.; Kottelat, J.; Prescimone, A.; Häussinger, D. Synthesis of chiral nine and twelve-membered cyclic polyamines from natural building blocks. *Chem. Commun.* **2019**, *55*, 4715–4718. (f) Joss, D.; Bertrams, M.-S.; Häussinger, D. A sterically overcrowded, isopropyl-substituted lanthanide chelating tag for protein PCS NMR spectroscopy: Synthesis of its macrocyclic scaffold and benchmarking on ubiquitin S57C and hCA II S166C. *Chem.–Eur. J.* **2019**, DOI: [10.1002/chem.201901692](https://doi.org/10.1002/chem.201901692).

(6) Carr, R.; Evans, N. H.; Parker, D. Lanthanide complexes as chiral probes exploiting circularly polarized luminescence. *Chem. Soc. Rev.* **2012**, *41*, 7673–7686.

(7) (a) Law, G.-L.; Andolina, C. M.; Xu, J.; Luu, V.; Rutkowski, P. X.; Muller, G.; Shuh, D. K.; Gibson, J. K.; Raymond, K. N. Circularly polarized luminescence of curium: a new characterization of the 5f actinide complexes. *J. Am. Chem. Soc.* **2012**, *134*, 15545–15549. (b) Dai, L.; Lo, W.-S.; Coates, I. D.; Pal, R.; Law, G.-L. New class of bright and highly stable chiral cyclen europium complexes for circularly polarized luminescence applications. *Inorg. Chem.* **2016**, *55*, 9065–9070.

(8) Liu, W.-M.; Overhand, M.; Ubbink, M. The application of paramagnetic lanthanoid ions in NMR spectroscopy on proteins. *Coord. Chem. Rev.* **2014**, *273*, 2–12.

(9) (a) Sherry, A. D.; Wu, Y. The importance of water exchange rates in the design of responsive agents for MRI. *Curr. Opin. Chem. Biol.* **2013**, *17*, 167–174. (b) Siriwardena-Mahanama, B. N.; Allen, M. J. Strategies for optimizing water-exchange rates of lanthanide-based contrast agents for magnetic resonance imaging. *Molecules* **2013**, *18*, 9352–9381.

(10) (a) Aime, S.; Barge, A.; Bruce, J. I.; Botta, M.; Howard, J. A.; Moloney, J. M.; Parker, D.; De Sousa, A. S.; Woods, M. NMR, relaxometric, and structural studies of the hydration and exchange dynamics of cationic lanthanide complexes of macrocyclic tetraamide ligands. *J. Am. Chem. Soc.* **1999**, *121*, 5762–5771. (b) Dunand, F. A.; Aime, S.; Merbach, A. E. First ^{17}O NMR Observation of Coordinated Water on Both Isomers of $[\text{Eu}(\text{DOTAM})(\text{H}_2\text{O})]^{3+}$: A Direct Access to Water Exchange and its Role in the Isomerization I. *J. Am. Chem. Soc.* **2000**, *122*, 1506–1512.

(11) Wang, G.-B.; Wang, L.-F.; Li, C.-Z.; Sun, J.; Zhou, G.-M.; Yang, D.-C. A facile and efficient method for the selective deacylation of *N*-arylacetamides and 2-chloro-*N*-arylacetamides catalyzed by SOCl_2 . *Res. Chem. Intermed.* **2012**, *38*, 77–89.

(12) Seitz, M.; Raymond, K. N. Efficient Route to Highly Water-Soluble Aromatic Cyclic Hydroxamic Acid Ligands. *Eur. J. Org. Chem.* **2008**, *2008*, 2697–2700.

(13) Kamioka, S.; Takahashi, T.; Kawauchi, S.; Adachi, H.; Mori, Y.; Fujii, K.; Uekusa, H.; Doi, T. Chiral tetraazamacrocycles having four pendant arms. *Org. Lett.* **2009**, *11*, 2289–2292.

(14) Terreno, E.; Castelli, D. D.; Viale, A.; Aime, S. Challenges for molecular magnetic resonance imaging. *Chem. Rev.* **2010**, *110*, 3019–3042.

(15) Zinna, F.; Di Bari, L. Lanthanide circularly polarized luminescence: bases and applications. *Chirality* **2015**, *27*, 1–13.

(16) Leonzio, M.; Melchior, A.; Faura, G.; Tolazzi, M.; Zinna, F.; Di Bari, L.; Piccinelli, F. Strongly Circularly Polarized Emission from Water-Soluble Eu(III)- and Tb(III)-Based Complexes: A Structural and Spectroscopic Study. *Inorg. Chem.* **2017**, *56* (8), 4413–4422.

(17) Lunkley, J. L.; Shirotani, D.; Yamanari, K.; Kaizaki, S.; Muller, G. Extraordinary circularly polarized luminescence activity exhibited by cesium tetrakis(3-heptafluoro-butyl-*l*-(+)-camphorato) Eu(III) complexes in EtOH and CHCl_3 solutions. *J. Am. Chem. Soc.* **2008**, *130* (42), 13814–13815.

(18) Bozoklu, G.; Gateau, C.; Imbert, D.; Pecaut, J.; Robeyns, K.; Filinchuk, Y.; Memon, F.; Muller, G.; Mazzanti, M. Metal-controlled diastereoselective self-assembly and circularly polarized luminescence of a chiral heptanuclear europium wheel. *J. Am. Chem. Soc.* **2012**, *134* (20), 8372–8375.